Athenex Inc (NASDAQ:ATNX) Receives Average Recommendation of “Buy” from Analysts

Athenex Inc (NASDAQ:ATNX) has been given a consensus rating of “Buy” by the nine research firms that are currently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $20.40.

ATNX has been the topic of several research analyst reports. Zacks Investment Research upgraded shares of Athenex from a “sell” rating to a “hold” rating in a report on Wednesday, May 29th. BidaskClub lowered shares of Athenex from a “hold” rating to a “sell” rating in a report on Wednesday, March 13th. Royal Bank of Canada restated an “outperform” rating on shares of Athenex in a report on Tuesday, March 12th. SunTrust Banks initiated coverage on shares of Athenex in a report on Friday, March 29th. They issued a “buy” rating and a $20.00 price objective on the stock. Finally, CIBC started coverage on shares of Athenex in a report on Thursday, May 2nd. They issued an “outperform” rating and a $20.00 price objective on the stock.

In other Athenex news, CEO Johnson Yiu Nam Lau purchased 4,000 shares of the business’s stock in a transaction on Monday, March 18th. The shares were bought at an average cost of $12.52 per share, for a total transaction of $50,080.00. Following the completion of the purchase, the chief executive officer now directly owns 2,936,236 shares of the company’s stock, valued at $36,761,674.72. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jordan Kanfer purchased 2,500 shares of the business’s stock in a transaction on Thursday, June 6th. The shares were acquired at an average price of $15.01 per share, for a total transaction of $37,525.00. Following the completion of the purchase, the director now directly owns 4,184 shares of the company’s stock, valued at $62,801.84. The disclosure for this purchase can be found here. Insiders have acquired 150,000 shares of company stock worth $1,886,815 over the last quarter. Insiders own 18.80% of the company’s stock.

Large investors have recently modified their holdings of the business. BNP Paribas Arbitrage SA increased its stake in Athenex by 913,400.0% during the first quarter. BNP Paribas Arbitrage SA now owns 9,135 shares of the company’s stock worth $112,000 after purchasing an additional 9,134 shares during the period. Prudential Financial Inc. purchased a new stake in Athenex during the fourth quarter worth about $147,000. Virginia Retirement Systems ET AL purchased a new stake in Athenex during the first quarter worth about $158,000. Metropolitan Life Insurance Co. NY increased its stake in Athenex by 356.6% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 14,245 shares of the company’s stock worth $181,000 after purchasing an additional 11,125 shares during the period. Finally, Trexquant Investment LP purchased a new stake in Athenex during the first quarter worth about $194,000. Institutional investors own 31.85% of the company’s stock.

Shares of ATNX opened at $16.95 on Thursday. The stock has a market capitalization of $1.11 billion, a P/E ratio of -11.77 and a beta of -0.94. Athenex has a 12-month low of $9.38 and a 12-month high of $20.90. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.85 and a current ratio of 2.22.

Athenex (NASDAQ:ATNX) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.08). The company had revenue of $25.31 million during the quarter, compared to analysts’ expectations of $19.55 million. Athenex had a negative net margin of 189.86% and a negative return on equity of 96.55%. Analysts expect that Athenex will post -1.77 earnings per share for the current year.

Athenex Company Profile

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform.

Featured Story: What is the Moving Average Convergence Divergence (MACD) oscillator?

Analyst Recommendations for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.